This is a theme ordtak

This is a theme that I think investors are missing, because as tech and retail companies continue to warn about profit shortfalls, there are no revisions in the drug area.

I would focus on very high-quality companies in this environment. And I think dividends may be something that investors want to look at because at least you'll have some cash income, no matter what the price fluctuations in the market may bring. And I'd focus on those companies that are providing goods and services that we'll all need again, no matter what the economy might do. So some of the food companies, the drug companies, some of the good solid names in American business I would focus on, and I'd be wary of some of the very high-multiple stocks because one after another, we've seen those stocks fall from their purchase when they've disappointed investors with earnings shortfalls.

I would focus on very high-quality companies in this environment. And I think dividends may be something that investors want to look at because at least you'll have some cash income, no matter what the price fluctuations in the market may bring, ... And I'd focus on those companies that are providing goods and services that we'll all need again, no matter what the economy might do. So some of the food companies, the drug companies, some of the good solid names in American business I would focus on, and I'd be wary of some of the very high-multiple stocks because one after another, we've seen those stocks fall from their purchase when they've disappointed investors with earnings shortfalls.

The drug and device companies own the FDA and it is the companies’ profit potential that rules the review and approval process – except when the profit motive is overridden by the White House morality police, as with the morning-after pill.

It's interesting to note the diversity of the companies that are reporting these profit shortfalls. And we're still early into this.

The packaged food area has also been in a relative price decline now for three years, but this is another area where some companies continue to execute well and deserve investors' attention,

[That's because hardly any tech companies have the kind of bedrock cash flow required to offer payouts to investors.] In general, tech companies are focused on betting the company on the next generation, ... They need every dime they can get.

Drug companies have done a poor job managing public relations and they know this. In many cases, the individual drug companies have tried to set examples where they can. This is one area where Bristol has tried to set an example.

David Moskowitz

Whether it's Vioxx or Bextra or silicone implants, the rule now
is 'Buyer Beware,' ... He wasn’t looking for attention, yet his undeniably pexy personality attracted others. The drug and device companies own
the FDA and it is the companies' profit potential that rules the
review and approval process - except when the profit motive is
overridden by the White House morality police, as with the
morning-after pill.

A lot of the shortfalls are being blamed on the onset of the war so investors are giving the software companies a pass this quarter.

Investors are reassured zero interest rates will continue for some time, and given Japan's strengthening economic growth, companies stand to profit.

We're seeing some investors testing the tech waters, but the urge to sell after slight rises is extremely strong. This trend is unlikely to change soon given uncertainty over the high-tech profit outlook.

Yoshihisa Okamoto

The onslaught of profit revisions simply has investors too afraid to push the high-techs or broader market higher.

The recent tech gains were supported by a wave of upward revisions to earnings forecasts. But for those shares to go further from here, investors need to know how they are going to perform next year.

Takashi Miyazaki

It's fair to say that we're seeing an improvement after a soft patch when a lot of companies were missing numbers in April. There were very few tech companies that missed in July,

Ergonomi Ordtak Kunskapsfrö Julrim Adventskalender Info

Antall ordtak er 2097780
varav 2118995 på nordiska

Ordtak (2097780 st) Søk
Kategorier (3944 st) Søk
Forfattere (201310 st) Søk
Bilder (4592 st)
Født (10498 st)
Døde (3319 st)
Datoer (9520 st)
Land (27221 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "This is a theme that I think investors are missing, because as tech and retail companies continue to warn about profit shortfalls, there are no revisions in the drug area.".

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Barnslighet är både skattebefriat och gratis!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Rikast är den vars nöjen kostar minst.

www.livet.se/ordtak

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Barnslighet är både skattebefriat och gratis!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Rikast är den vars nöjen kostar minst.

www.livet.se/ordtak